Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T4BL
|
|||
| Former ID |
DCL000008
|
|||
| Drug Name |
Neovastat
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 1 | [1] | |
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Phase 1 | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Ferrer; Hospira; LG Life Sciences; AEterna Zentaris
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 2 | Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. | |||
| REF 3 | Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol. 2005 Feb;43(1):11-6. | |||
| REF 4 | The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol. 2002 Feb;20(2):299-303. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.